On the other hand, Msln is known to be highly expressed in several human tumors including mesothelioma, ovarian cancer, pancreatic adenocarcinoma, lung adenocarcinoma, and cholangiocyte carcinoma [63,64,65], and thus it has attracted attention as a potential target for anti-cancer therapy [61,66] by newly developed strategies of immunotherapy using recombinant immunotoxin, antibody-drug conjugates, chimeric monoclonal antibody, and chimeric antigen receptor T cell therapy [67,68,69,70,71,72,73,74]. The gene discussed is MSLN; the disease is ovarian cancer.